KYMR Q2 2025 Earnings — Kymera Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

KYMRKymera Therapeutics, Inc.

$7B

Q2 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$11M-55.3% YoY

Gross Profit

$9M81.8% margin

Operating Income

-$85M-736.8% margin

Net Income

-$77M-667.6% margin

EPS (Diluted)

$-0.95

QoQ Revenue Growth

-48.1%

Cash Flow

Operating Cash Flow

-$60M

Free Cash Flow

-$61M

Stock-Based Comp.

$15M

Balance Sheet

Total Assets

$1.1B

Total Liabilities

$160M

Stockholders' Equity

$971M

Cash & Equivalents

$336M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$11M	$26M	-55.3%
Gross Profit	$9M	$26M	-63.4%
Operating Income	-$85M	-$51M	-66.0%
Net Income	-$77M	-$42M	-82.1%